U.S. Markets closed

PureTech Health plc (PRTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
37.00-2.00 (-5.13%)
At close: 03:56PM EST

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333

Full Time Employees250

Key Executives

NameTitlePayExercisedYear Born
Ms. Daphne ZoharFounder, CEO & Exec. Director1.24MN/A1971
Dr. Bennett M. Shapiro M.D.Co-Founder & Board Advisor95kN/A1940
Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCDCo-Founder & Non-Exec. Director245kN/A1949
Dr. Bharatt M. ChowriraPres, Chief of Bus. & Strategy, Sec. and Exec. DirectorN/AN/A1965
Dr. David R. Elmaleh Ph.D.Co-Founder & Sr. AdvisorN/AN/A1948
Dr. George Farmer Ph.D.Chief Financial OfficerN/AN/AN/A
Dr. Joseph B. BolenChief Scientific OfficerN/AN/A1954
Ms. Allison Mead TalbotHead of Communications & Investor RelationsN/AN/AN/A
Mr. Spencer BallSr. VP of HRN/AN/AN/A
Dr. Eric ElenkoChief Innovation OfficerN/AN/A1973
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

PureTech Health plc’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.